Selective contribution of waist circumference reduction on the improvement of sleep-disordered breathing in patients hospitalized with type 2 diabetes mellitus

Internal Medicine

Volumn 50, Issue 18, 2011, Pages 1895-1903

  Kashine, Susumu ^a   Kishida, Ken ^a   Funahashi, Tohru ^a   Yasuda, Tetsuyuki ^a   Okita, Kohei ^a   Matsuzawa, Yuji ^b   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY   (Japan)

^b SUMITOMO HOSPITAL   (Japan)

Author keywords

Adipocytokines; Sleep disordered breathing; Type 2 diabetes mellitus; Waist circumference reduction

Indexed keywords

1,5 ANHYDROSORBITOL; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; LEPTIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ABDOMINAL OBESITY; ADULT; AGED; ANTHROPOMETRIC PARAMETERS; APNEA HYPOPNEA INDEX; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DIABETIC NEUROPATHY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLYCEMIC CONTROL; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; INTRAABDOMINAL FAT; LABORATORY TEST; MALE; NECK CIRCUMFERENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; SLEEP DISORDERED BREATHING; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; POLYSOMNOGRAPHY; RISK FACTORS; SLEEP APNEA SYNDROMES; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 80052822949     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.5669     Document Type: Article

References (54)

1. Findley LJ, Fabrizio M, Thommi G, Suratt PM. Severity of sleep apnea and automobile crashes. N Engl J Med 320: 868-869, 1989.
2. Gami AS, Howard DE, Olson EJ, Somers VK. Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med 342: 1206-1214, 2005.
3. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoeahypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365: 1046-1053, 2005.
4. Katsumata K, Okada T, Miyao M, Katsumata Y. High incidence of sleep apnea syndrome in a male diabetic population. Diabetes Res Clin Pract 13: 45-51, 1991.
5. Sridhar GR, Madhu K. Prevalence of sleep disturbances in diabetes mellitus. Diabetes Res Clin Pract 23: 183-186, 1994.
6. Resnick HE, Redline S, Shahar E, et al; Sleep Heart Health Study. Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. Diabetes Care 26: 702-709, 2003.
7. Reichmuth KJ, Austin D, Skatrud JB, Young T. Association of sleep apnea and type II diabetes: a population-based study. Am J Respir Crit Care Med 172: 1590-1595, 2005.
8. Einhorn D, Stewart DA, Erman MK, Gordon N, Philis-Tsimikas A, Casal E. Prevalence of sleep apnea in a population of adults with type 2 diabetes mellitus. Endocr Pract 13: 355-362, 2007.
9. Pascualy R. Sleep apnea and type 2 diabetes. A vicious circle. Diabetes Self Manag 24: 29-30, 2007.
10. Martins RC, Andersen ML, Tufik S. The reciprocal interaction between sleep and type 2 diabetes mellitus: facts and perspectives. Braz J Med Biol Res 4: 180-187, 2008.
11. Tasali E, Mokhlesi B, Van Cauter E. Obstructive sleep apnea and type 2 diabetes: interacting epidemics. Chest 133: 496-506, 2008.
12. Kashine S, Kishida K, Funahashi T, et al. Characteristics of sleepdisordered breathing in Japanese patients with type 2 diabetes mellitus. Metabolism 59: 690-696, 2010.
13. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 290: 1906-1914, 2003.
14. Ferini-Strambi L, Fantini ML. Cerebrovascular diseases and sleepdisordered breathing. Clin Exp Hypertens 28: 225-231, 2006.
15. Budhiraja R, Budhiraja P, Quan SF. Sleep-disordered breathing and cardiovascular disorders. Respir Care 55: 1322-1332, 2010.
16. Shaw JE, Punjabi NM, Wilding JP, Alberti KG, Zimmet PZ; International Diabetes Federation Taskforce on Epidemiology and Prevention. Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. Diabetes Res Clin Pract 81: 2-12, 2008.
17. Shinohara E, Kihara S, Yamashita S, et al. Visceral fat accumulation as an important risk factor for obstructive sleep apnoea syndrome in obese subjects. J Intern Med 241: 11-18, 1997.
18. Vgontzas AN, Bixler EO, Chrousos GP. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med 254: 32-44, 2003.
19. Vgontzas AN, Bixler EO, Chrousos GP. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med 254: 32-44, 2003.
20. Kishida K, Funahashi T, Matsuzawa Y, Shimomura I. Visceral adiposity as a target for the management of the metabolic syndrome: A Japanese perspective. Ann Med 2011 in press.
21. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114: 1752-1761, 2004.
22. Nakagawa Y, Kishida K, Kihara S, et al. Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome. Am J Physiol Endocrinol Metab 294: E778-E784, 2008.
23. Nakagawa Y, Kishida K, Kihara S, Yoshida R, Funahashi T, Shimomura I. Nocturnal falls of adiponectin levels in sleep apnea with abdominal obesity and impact of hypoxia-induced dysregulated adiponectin production in obese murine mesenteric adipose tissue. J Atheroscler Thromb 18: 240-247, 2011.
24. Huxley R, James WP, Barzi F, et al; Obesity in Asia Collaboration. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes Rev 9: 53-61, 2008.
25. Anan F, Masaki T, Eto T, et al. Visceral fat accumulation is a significant risk factor for white matter lesions in Japanese type 2 diabetic patients. Eur J Clin Invest 39: 368-374, 2009.
26. Anan F, Masaki T, Umeno Y, et al. Correlations of visceral fat accumulation and atherosclerosis in Japanese patients with type 2 diabetes mellitus. Metabolism 57: 280-284, 2008.
27. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14: 540-545, 1991.
28. Collop NA, Anderson WM, Boehlecke B, et al; Portable Monitoring Task Force of the American Academy of Sleep Medicine. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 3: 737-747, 2007.
29. Anonymous. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 22: 667-689, 1999.
30. Anonymous. Task force of the European society of cardiology the North American Society of pacing and electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation 93: 1043-1065, 1996.
31. Teramoto T, Sasaki J, Ueshima H, et al. Metabolic syndrome. J Atheroscler Thromb 15: 1-5, 2008.
32. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83, 1999.
33. Maeda N, Takahashi M, Funahashi T, et al. PPAR gamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: 2094-2099, 2001.
34. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with endstage renal disease. J Am Soc Nephrol 13: 134-141, 2002.
35. Roman S, Pandolfino JE. Environmental -lifestyle related factors. Best Pract Res Clin Gastroenterol 24: 847-859, 2010.
36. Egger G, Dixon J. Obesity and chronic disease: always offender or often just accomplice? Br J Nutr 102: 1238-1242, 2009.
37. Dubbert PM, Carithers T, Sumner AE, et al. Obesity, physical inactivity, and risk for cardiovascular disease. Am J Med Sci 324: 116-126, 2002.
38. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36: 54-59, 1987.
39. Nakajima T, Fujioka S, Tokunaga K, Matsuzawa Y, Tarui S. Correlation of intraabdominal fat accumulation and left ventricular performance in obesity. Am J Cardiol 64: 369-373, 1989.
40. Kanai H, Matsuzawa Y, Kotani K, et al. Close correlation of intraabdominal fat accumulation to hypertension in obese women. Hypertension 16: 484-490, 1990.
41. Fujioka S, Matsuzawa Y, Tokunaga K, et al. Improvement of glucose and lipid metabolism associated with selective reduction of intra-abdominal visceral fat in premenopausal women with visceral fat obesity. Int J Obes 15: 853-859, 1991.
42. Matsuzawa Y, Fujioka S, Tokunaga K, Tarui S. Classification of obesity with respect to morbidity. Proc Soc Exp Biol Med 200: 197-201, 1992.
43. Kanai H, Tokunaga K, Fujioka S, Yamashita S, Kameda-Takemura KK, Matsuzawa Y. Decrease in intra-abdominal visceral fat may reduce blood pressure in obese hypertensive women. Hypertension 27: 125-129, 1996.
44. Matsuzawa Y. Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc Jpn Acad Ser B Phys Biol Sci 86: 131-141, 2010.
45. Nakamura T, Tokunaga K, Shimomura I, et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107: 239-246, 1994.
46. Fujimoto WY, Bergstrom RW, Boyko EJ, et al. Visceral adiposity and incident coronary heart disease in Japanese-American men. The 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. Diabetes Care 22: 1808-1812, 1999.
47. Kadowaki T, Sekikawa A, Murata K, et al. Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study. Int J Obes (Lond) 30: 1163-1165, 2006.
48. Funahashi T, Nakamura T, Shimomura I, et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 38: 202-206, 1999.
49. Funahashi T, Matsuzawa Y. Metabolic syndrome: clinical concept and molecular basis. Ann Med 39: 482-494, 2007.
50. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 25: 2062-2068, 2005.
51. Suganami T, Tanimoto-Koyama K, Nishida J, et al. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acidinduced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 27: 84-91, 2007.
52. Suganami T, Ogawa Y. Adipose tissue macrophages: their role in adipose tissue remodeling. J Leukoc Biol 88: 33-39, 2010.
53. Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J 70: 1437-1442, 2006.
54. Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 68: 975-981, 2004.